• 1
    Andersen BL. Psychological interventions for cancer patients to enhance the quality of life. J Consult Clin Psychol. 1992; 60: 552568.
  • 2
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485493.
  • 3
    Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000; 18: 26952701.
  • 4
    Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative chemotherapy for breast carcinoma. Cancer. 1999; 85: 640650.
  • 5
    Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003; 21: 41754183.
  • 6
    van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998; 90: 210218.
  • 7
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995; 4: 6166.
  • 8
    Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003; 9: 967982.
  • 9
    Wefel JS, Lenzi R, Theriault R, Buzder AU, Cruickshark S, Meyers CA. “Chemobrain” in breast cancer? A prologue. Cancer. In press.
  • 10
    Wechsler D. Wechsler adult intelligence scale—revised. San Antonio: The Psychological Corporation, 1981.
  • 11
    Reitan RM, Davison LA. Clinical neuropsychology: current status and applications. New York: Hemisphere Publishing Corporation, 1974.
  • 12
    Hannay HJ, Levin HS. Selective reminding test: an examination of the equivalence of four forms. J Clin Exp Neuropsychol. 1985; 7: 251263.
  • 13
    Fletcher JM. Memory for verbal and nonverbal stimuli in learning disabled subgroups: analysis by selective reminding. J Exp Child Psychol. 1985; 40: 244259.
  • 14
    Benton AL, Hamsher K. Multilingual aphasia examination. Iowa City: AJA Associates, 1983.
  • 15
    DeFilippis NA, McCampbell E, Rogers P. Development of a booklet form of the Category Test: normative and validity data. J Clin Neuropsychol. 1979; 1: 339342.
  • 16
    Klove H. Clinical neuropsychology. Med Clin North Am. 1963; 47: 16471658.
  • 17
    Hathaway SR, McKinley JC. Minnesota multiphasic personality inventory. Minneapolis: National Computer Systems, 1970.
  • 18
    Cella DF. FACT manual. Version 3. Chicago: Rush-Presbyterian–St. Luke's Medical Center, 1996.
  • 19
    Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991; 59: 1219.
  • 20
    Greene RL. The MMPI-2/MMPI: an interpretive manual. Boston: Allyn and Bacon, 1991.
  • 21
    Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996; 2: 477481.
  • 22
    Pirzada NA, Ali II, Dafer RM. Flourouracil-induced neurotoxicity. Ann Pharmacother. 2000; 34: 3538.
  • 23
    Tuxen MK, Werner HS. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994; 20: 191214.
  • 24
    Choi SM, Lee SH, Yang YS, Kim BC, Kim MK, Cho KH. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001; 16: 328334.